Articles tagged with Breast Cancer
A new clinical practice resource provides valuable information for healthcare professionals caring for individuals with pathogenic variants in the CHEK2 gene. The resource assesses personalized risk estimates based on family history, specific variant, and other factors.
Researchers developed a strategy to predict chemotherapy response in triple negative breast cancer (TNBC) using the Kinase Inhibitor Pulldown Assay (KIPA). The study identified a seven-purine-binding protein signature that predicted chemotherapy sensitivity and favorable clinical outcomes.
Researchers have created a biomedical compound that can block the interaction of metastasis-inducing protein S100A4 with its target inside the cell. The compound inhibits properties associated with metastasis at very low doses, showing potential therapeutic role in breast cancer treatment.
A new study by researchers at the National Institutes of Health found that women diagnosed and treated for breast cancer have increased biological aging compared to those who remain free of breast cancer. Radiation therapy showed the strongest association with faster biological aging, while surgery had no effect.
Researchers found that breast cancer survivors experience a faster rate of biological aging, with higher rates of age-related diseases and physical cognitive decline. Radiation therapy was found to be particularly impactful on aging rates, contributing to the conversation on how to best treat and care for breast cancer survivors.
Researchers at NUS developed a new photodynamic therapy that selectively kills breast cancer cells without damaging surrounding tissues. The treatment uses a biocompatible silicone implant loaded with nanoparticles activated by near-infrared light, reducing the risk of toxicity and improving tumour control.
Rice University chemist Han Xiao has won a $3.2 million research grant from the National Cancer Institute to develop an epigenetic inhibitor targeting bone metastasis. The drug, based on existing bisphosphonates, aims to prevent cancer cells from spreading to other organs without affecting normal tissues.
Researchers have discovered a mechanism leading to resistance in luminal breast cancer and propose using the approved osteoporosis drug denosumab to block RANK protein, promoting effectiveness of CDK4/6 inhibitors. This could lead to new treatment options for patients with metastatic breast cancer.
Researchers at Georgetown University Medical Center discovered the biological mechanism of TTP488, an experimental drug that impairs aggressive triple-negative breast cancer from metastasizing. The finding enables clinical trials to explore the drug's effectiveness in preventing TNBCs from spreading, offering new hope for patients with...
Researchers found that healthy breast adipocytes secrete IGFBP2, which acts as a barrier against invasive breast cancer progression. Lower IGFBP2 levels with age may contribute to increased breast cancer risk.
A new study led by Sandra Casimiro and Luís Costa found a promising molecular target, the RANK signaling pathway, that could be used in combination with standard care to avoid resistance to treatment in metastatic breast cancer. High levels of RANK in cancer cells are associated with resistance to treatment with CDK4/6 inhibitors.
A new study by researchers at Dartmouth Cancer Center shows that a combination of estrogen and PARP inhibitors can effectively treat advanced ER+ breast cancer by damaging cancer cells and preventing DNA repair. The treatment strategy has been shown to be effective regardless of BRCA1 or BRCA2 genetic mutations.
Researchers at the University of Alberta have discovered a correlation between chemotherapy-induced changes to gut bacteria and unhealthy weight gain in breast cancer patients. The study found that these patients gained abdominal fat and experienced inflammation, with significant changes to their gut microbiome.
A new study reveals that preoperative hydroxyprogesterone administration can improve disease-free and overall survival in patients with node-positive breast cancer by modulating cellular stress response and negative regulation of inflammation. Non-coding RNAs, such as DSCAM-AS1, play a regulatory role in this process.
An epigenetic study of over 18,000 people in Scotland identified associations between certain DNA modifications and increased risks of breast cancer, type II diabetes, and chronic obstructive pulmonary disease (COPD). The findings provide new insights into the underlying mechanisms of these diseases.
Inflammatory breast cancer is a rare and aggressive form of breast cancer with poor outcomes. Research highlights the role of ERβ as a mediator of estrogen signaling, demonstrating its tumor suppressive effects in preclinical models. ERβ's antimetastatic activity may hold promise for improving treatment options for IBC.
A study found that certain genetic mutations are associated with treatment-resistant breast cancer in young women, but not older women. The research proposes a new paradigm for classifying and studying all types of cancer.
A new study has created the world's largest map of normal breast tissue, highlighting 12 major cell types and 58 biological cell states. The atlas also identifies differences based on ethnicity, age, and menopause status, providing a powerful resource for researchers studying breast cancer and other diseases.
A newly discovered radionuclide-based agent (CB-2PA-NT) has shown high tumor uptake, sustained retention, and contrast in preclinical models. Targeting neurotensin receptors, CB-2PA-NT expands precision medicine for cancer diagnosis and treatment.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
Researchers at the University of Malaga develop a new therapy using manual techniques and stretching to reduce pain and improve mobility in women with axillary web syndrome after breast cancer. The therapy, consisting of 15 sessions, has shown significant results in reducing evolution time of lymphatic thrombi.
Researchers found that ChatGPT 4 can accurately identify appropriate imaging services for breast cancer screening and breast pain. The AI model outperformed its predecessor, ChatGPT 3.5, in providing evidence-backed guidelines for radiologists.
A new study reveals how breast cancer cells suppress anti-cancer immune responses in the lymph nodes to survive and spread. Researchers found that some cancer cells exhibit elevated expression of MHC class II proteins, which are involved in initiating immune responses.
A new study reveals that the protein complex BCDX2 plays a critical role in DNA repair, suggesting mutations in this complex could lead to cancer. The research also highlights the importance of screening for mutations in people with a family history of breast and ovarian cancers.
A team of researchers at the University of Tennessee Health Science Center has received a $3.07 million grant from the National Cancer Institute to develop new drugs targeting microtubules for breast cancer treatment. The goal is to improve overall survival and quality of life for patients with metastatic breast cancer.
A UMass Amherst biostatistician is developing statistical tools to better predict breast cancer survival rates and survival time after recurrence. The methods, funded by an NIH grant, will also have a broad application for other chronic diseases, such as those involving hormones and biomarkers.
A new study published in the Journal of the American College of Surgeons found that people who live in historically redlined areas are less likely to be screened for breast, colorectal, and cervical cancer. The legacy of redlining continues to contribute to significant disparities in cancer screening rates.
Research suggests that aromatase inhibitors can limit the effectiveness of weight loss medications in breast cancer survivors. Studies have shown that these medications are less effective in women taking aromatase inhibitors, leading to reduced weight loss and increased risk of health complications.
Researchers developed tiny nano-sized pores that can detect specific proteins in complex biological fluids, such as blood. The breakthrough enables fast and accurate disease diagnosis, potentially leading to earlier interventions and improved treatment outcomes.
A recent study has found that impaired histone inheritance accelerates breast cancer growth and metastasis by disrupting the epigenetic state of cells. This disruption leads to the reactivation of genes associated with development, promoting tumor progression.
A new review paper suggests ACSL4 status as a biomarker for breast cancer subtype classification and predictor of response to hormone-based therapies. The enzyme may also serve as a target for developing new treatment modalities in quadruple negative breast cancer.
Researchers from Medical College of Wisconsin found that older breast cancer survivors, particularly those exposed to chemotherapy, showed greater epigenetic aging than their same-aged peers without cancer. This acceleration in biological aging may be associated with worse functional outcomes and quality of life for these patients.
Researchers developed a new method, photoacoustic spectral analysis (PASA), to analyze the tumor microenvironment without invasive procedures. The technique uses laser light and sound waves to identify different types of tumors with high accuracy.
A study published in The BMJ found that women diagnosed with early stage breast cancer today can expect to become long term cancer survivors. The average risk of dying from breast cancer in the five years after a diagnosis has fallen from 14% to 5% since the 1990s.
A new study found significant reductions in breast, colorectal and prostate cancers as well as melanoma diagnoses in Alberta during the COVID-19 pandemic. Diagnoses dropped by 43% for melanoma, 36% for colorectal and prostate, and 33% for breast cancer during the 'state of emergency' phase.
A recent study published in the journal CANCER found that supplemental ultrasound screening can detect breast cancers missed by mammography, but it requires careful targeting of high-risk groups. Women with dense breasts are at higher risk of interval invasive breast cancer, and clinicians should consider other breast cancer risk facto...
A new study found that obesity is associated with an increased risk of certain cancers, with stronger links in female patients for gallbladder and endometrial cancer. The study also revealed differential effects between sexes on colorectal, esophageal, and liver cancer.
Research from Johns Hopkins Medicine found that Black and Hispanic female breast cancer survivors have higher death rates from second cancers compared to other ethnic groups. The risk of death from a second cancer is 12% higher among non-Hispanic Black survivors and 8% higher among Hispanic survivors.
The study, published in JAMA Oncology, found that the percentage of cancer survivors reporting functional limitations has more than doubled over the past 20 years. The adjusted prevalence of functional limitation was highest among pancreatic and lung cancer survivors, while melanoma survivors had the lowest rate.
A team of researchers discovered a process that helps breast cancer cells implant themselves in certain places in the body, leading to poorer prognosis. Overproduction of NNMT is key to metastasis, producing excessive collagen that enables cancer cells to survive and adapt.
A network meta-analysis of 10 studies found expert panel-based and computer-based aesthetic outcome evaluation scored lower than patient-perceived outcomes. Standardization of tools with racially and culturally inclusive patient-reported measures is needed to improve clinical assessment of breast cancer patients.
Researchers found that only 6.8% of cancer patients underwent genetic testing within two years of diagnosis, with lower rates among Black, Hispanic, and Asian patients. The low rates are attributed to lack of integration of test results into cancer management and prevention.
A recent study published in Radiology found that AI algorithms performed better than the standard Breast Cancer Surveillance Consortium (BCSC) risk model for predicting five-year breast cancer risk. The AI models extracted hundreds of additional mammographic features, leading to improved predictive performance.
Researchers analyzed BORIS mutations and protein expression in breast cancer tissue samples, finding frequent mutations associated with breast carcinoma progression. The study suggests the BORIS gene as a potential biomarker for breast cancer.
Erdafitinib achieves tumor-agnostic benefits across 16 cancer types, including urothelial, lung, and other cancers. The trial demonstrated a disease control rate of 73.7% and clinical benefit rate of 45.6%, with notable improvements in pancreatic and cholangiocarcinoma patients.
Researchers discovered that targeting specific blood vessel enzymes can enhance immunotherapy effectiveness and prevent breast cancer metastasis. By disabling the enzyme DNMT1 in blood vessels, doctors may bolster anti-tumor immune cells entry and increase patients' response to treatment.
A study found that adding ribociclib to hormone therapy significantly improves invasive disease-free survival rates in patients with stage 2 or 3 HR positive/HER2 negative breast cancer. The combination therapy reduced the risk of cancer recurrence by 25%, with a three-year invasive disease-free survival rate of 90.4%.
A Phase II trial led by MD Anderson Cancer Center showed that zanidatamab achieved a 41% confirmed objective response rate and durable responses in HER2-positive biliary tract cancer. This represents the largest study of a HER2-targeted drug in BTC, providing evidence for its potential as a new treatment option.
Researchers at UCLA Health highlight the impact of test results on lung cancer screening adherence and the potential unnecessary use of axillary ultrasound in breast cancer diagnostics. Meanwhile, a new AI system helps check endotracheal tube placement with high accuracy and user satisfaction.
At ASCO 2023, Sylvester Comprehensive Cancer Center experts are available to discuss a wide range of topics, including Sarcoma research, tumor agnostic precision oncology, and genitourinary cancers. The center's experts also share their perspectives on immunotherapy approaches for prostate cancer, breast cancer treatment, and melanoma.
A large study tracked CIPN in over 1,100 breast cancer patients treated with taxanes, showing persistent sensory and motor symptoms with more severe symptoms with paclitaxel than docetaxel. The study defines a risk prediction model to help doctors individualize patient care.
Researchers presented findings on pembrolizumab for brain metastases, virtual mind-body interventions for post-treatment survival, and dynamic HER2-low status in triple negative breast cancer. The studies aim to improve treatments and outcomes for patients with cancer.
Researchers at Baylor College of Medicine discovered that eliminating the gene SRC-3 in immune cells, specifically regulatory T cells (Tregs), triggered a lifelong anti-cancer response. This approach eradicated breast and prostate cancer tumors without negative side effects.
Researchers developed a novel endoscopic imaging system with a bioinspired sensor that can detect multiple fluorescent probes, enabling more accurate fluorescence-guided cancer surgery. The system showed improved spatial resolution and sensitivity in detecting tumors, paving the way for the adoption of multi-tracer FGS.
A clinical trial found that a telephone-based weight loss program can help breast cancer patients with overweight or obesity lower their weight by a significant degree. Women who received the program lost an average of 4.8% of their baseline body weight, compared to a 0.9% increase in the control group.
Dr. Kristin Rojas addresses quality of life concerns for breast cancer patients undergoing endocrine therapy, including sexual health, fertility preservation, and bone health. Her program, Music, has become a model for similar programs across the US, improving patient adherence to treatment.
A new study published in the Journal of the American College of Surgeons predicts a significant increase in cancer cases due to COVID-19 screening delays, with lung, breast, and colorectal cancers most affected. The study found that missed diagnoses during the pandemic may lead to delays in treatment and upstaging of disease.
Researchers found that distant cancers alter liver function by inducing fat accumulation and inflammation in liver cells. The process involves secretion of extracellular vesicles containing fatty acids, which reprogram the liver to resemble fatty liver disease.
Penn Medicine researchers will present results from clinical trials for recurrent glioblastoma and metastatic breast cancer. Experts will also present studies on serious illness conversations, Medicaid expansion impact, and infertility among female oncologists.
Researchers at Rensselaer Polytechnic Institute and Albany Medical College will use AI to develop a novel mesoscopic, multimodal preclinical imaging approach to test the hypothesis that drug distribution mediates tumor resistance. The goal is to improve targeted therapy for HER2-positive breast cancer.